Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026
Geron (Nasdaq: GERN) plans to release its third quarter 2026 financial results before the market opens on November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (Nasdaq: GERN) plans to release its third quarter 2026 financial results before the market opens on November 4, 2026. The release will include business highlights and be available on its investor website. A conference call and webcast will follow at 8:00 a.m. Eastern Time, with live and archived audio available at www.geron.com.
Details
Market Reaction – GERN
On Oct 21, the day this news came out, the latest delayed price for GERN is 4.03% below the previous close. Our momentum scanner has recorded 6 alerts for this stock so far that day. The latest delayed price is $1.19.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Results release date
- November 4, 2026
- Third quarter 2026 financial results, before market open
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that it will release its third quarter 2026 financial results and business highlights before the market opens on Wednesday, November 4, 2026, via press release, which will be available on the Investors section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available through the Investors section of the Company’s website at www.geron.com.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
